How would a case with two tumors in different organs be coded for the registry?

How would a case with two tumors in different organs be coded for the registry?

• A. Code only the first tumor; ignore second
• B. Merge into a single record with averaged data
• C. Use a generic code for multiple primaries
• D. Code each primary site with its own ICD-O topography and morphology; count as two primaries if rules indicate independence (e.g., separate organs, different histology or confirmed as new primaries)

Answer: (D)

In cancer registry coding, every primary tumor is documented separately when it arises in a distinct organ or site, using its own ICD-O topography (site) and morphology (histology). If two tumors occur in different organs, they generally count as two primaries, provided there’s no evidence that one is a metastasis of the other. So you would code each tumor with its specific site and histology, and count them as two primaries because they are independent by location (and can be further distinguished if histology differs or if there is explicit confirmation that both are new primaries). This approach preserves accurate incidence and survival data by capturing the distinct diseases. Not coding only the first tumor or merging them would underrepresent the patient’s cancer burden, and using a generic code for multiple primaries would lose crucial site- and histology-specific information.

In cancer registry coding, every primary tumor is documented separately when it arises in a distinct organ or site, using its own ICD-O topography (site) and morphology (histology). If two tumors occur in different organs, they generally count as two primaries, provided there’s no evidence that one is a metastasis of the other. So you would code each tumor with its specific site and histology, and count them as two primaries because they are independent by location (and can be further distinguished if histology differs or if there is explicit confirmation that both are new primaries). This approach preserves accurate incidence and survival data by capturing the distinct diseases.

Not coding only the first tumor or merging them would underrepresent the patient’s cancer burden, and using a generic code for multiple primaries would lose crucial site- and histology-specific information.